IP Library Patent Application 14029069
Patent Application
App. No. 14/029,069

Antifungal Treatment

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/029,069
Abstract

A method of treating or preventing fungal infection, which includes identifying a plant or animal having a fungal infection and administering an effective amount of an anti-fungal composition to the plant or animal to reduce the fungal infection. In a preferred form of the present invention, the antifungal composition is compound 13 or 33 and is combined with an azole compound, such as fluconazole.

Claims (49)

1 . A method for treating fungal infection, comprising:

(a) identifying a plant or animal having a fungal infection; and

(b) administering an effective amount of an anti-fungal compound to the plant or animal, wherein the amount is effective to reduce the fungal infection and wherein the compound comprises formula IV.

2 . The method of claim 1 wherein the compound comprises a compound of formula (IV):

wherein is an alkane, alkene, or alkyne, and R 5 is selected from the group consisting of formulas (V), (VI), (VII), and (VIII):

or a salt, prodrug, solvate or hydrate thereof.

3 . The method of claim 2 wherein the compound further comprises a compound of formula (I):

wherein R 1 is >S or oxidized >S, R 2 and R 3 are independently selected from formulas (II) and (III):

and R 4 is >S or oxidized >S, or a salt, prodrug, solvate or hydrate thereof.

4 . The method of claim 1 wherein the histidine kinase-dependent anti-fungal compound comprises:

or a salt, prodrug, solvate or hydrate thereof.

5 . The method of claim 4 wherein the histidine kinase-dependent anti-fungal compound further comprises:

or a salt, prodrug, solvate or hydrate thereof.

6 . The method of claim 1 additionally comprising administering an amount of an azole compound effective to reduce fungal infection.

7 . The method of claim 6 wherein the azole is fluconazole.

8 . The method of claim 1 , wherein the compound is a histidine kinase-dependent antifungal compound.

9 . The method of claim 8 , wherein the histidine kinase is Drk1.

10 . A method for preventing a fungal infection, comprising:

administering an effective amount of a composition of formula IV to a plant or animal,

wherein the amount is effective to prevent a fungal infection.

11 . The method of claim 10 wherein the composition comprises a compound of formula (IV):

wherein is an alkane, alkene, or alkyne, and R 5 is selected from the group consisting of formulas (V), (VI), (VII), and (VIII):

or a salt, prodrug, solvate or hydrate thereof.

12 . The method of claim 11 wherein the composition further comprises a compound of formula (I):

wherein R 1 is >S or oxidized >S, R 2 and R 3 are independently selected from formulas (II) and (III):

and R 4 is >S or oxidized >S, or a salt, prodrug, solvate or hydrate thereof.

13 . The method of claim 10 wherein the composition comprises:

or a salt, prodrug, solvate or hydrate thereof.

14 . The method of claim 10 wherein the composition further comprises:

or a salt, prodrug, solvate or hydrate thereof.

15 . The method of claim 10 additionally comprising administering an amount of an azole compound effective to reduce fungal infection.

16 . The method of claim 10 wherein the azole is fluconazole.

17 . A pharmaceutical dosage form comprising an effective amount of the compound of claim 1 and a pharmaceutically suitable carrier system.

18 . The dosage form of claim 17 wherein the compound comprises a compound of formula (IV):

wherein is an alkane, alkene, or alkyne, and R 5 is selected from the group consisting of formulas (V), (VI), (VII), and (VIII):

or a salt, prodrug, solvate or hydrate thereof.

19 . The dosage form of claim 17 , wherein the dosage form comprises an oral, injection, infusion, inhalation, transdermal, or implant dosage form.

20 . The dosage form of claim 17 wherein the compound further comprises a compound of formula (I):

wherein R 1 is >S or oxidized >S, R 2 and R 3 are independently selected from formulas (II) and (III):

and R 4 is >S or oxidized >S, or a salt, prodrug, solvate or hydrate thereof.

21 . The dosage form of claim 18 additionally comprising an azole compound.

22 . The dosage form of claim 20 additionally comprising an azole compound.

23 . An agricultural preparation comprising the compound of claim 1 .

24 . The preparation of claim 23 wherein the compound comprises a compound of formula (IV):

wherein is an alkane, alkene, or alkyne, and R 5 is selected from the group consisting of formulas (V), (VI), (VII), and (VIII):

or a salt, prodrug, solvate or hydrate thereof.

25 . The preparation of claim 23 wherein the compound further comprises a compound of formula (I):

wherein R 1 is >S or oxidized >S, R 2 and R 3 are independently selected from formulas (II) and (III):

and R 4 is >S or oxidized >S, or a salt, prodrug, solvate or hydrate thereof.

Assignments (2)
CONFIRMATORY LICENSE Recorded Mar 15, 2018
From: UNIVERSITY OF WISCONSIN-MADISON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 045603/0481 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2013
From: TEBBETS, BRAD; KLEIN, BRUCE
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 031349/0417 →